Relationship between Prolactin, Chronic Kidney Disease, and Cardiovascular Risk
Open Access
- 22 June 2020
- journal article
- review article
- Published by Wiley in International Journal of Endocrinology
- Vol. 2020, 1-6
Abstract
CKD has a high prevalence worldwide, mainly due to its main etiologies—diabetes and hypertension. It has high cardiovascular morbidity and mortality, with traditional risk factors such as atherosclerosis, hypertension, diabetes, smoking, and left ventricular hypertrophy being common. Nontraditional cardiovascular risk factors, such as anemia, hyperparathyroidism, chronic inflammation, and microalbuminuria, are also well studied. Prolactin is a hormone not only related to lactation but also being considered a uremic toxin by some authors. It accumulates with loss of renal function, and it is associated with cardiovascular outcomes in both normal renal function population and CKD population. The purpose of this narrative review is to raise the main common aspects of CKD, prolactinemia, and cardiovascular risk.Keywords
This publication has 51 references indexed in Scilit:
- Prolactin Levels, Endothelial Dysfunction, and the Risk of Cardiovascular Events and Mortality in Patients with CKDClinical Journal of the American Society of Nephrology, 2012
- Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 DiabetesDiabetes Care, 2011
- The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis?Journal of Endocrinology, 2010
- Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysisThe Lancet, 2010
- Evaluation of Bromocriptine in the Treatment of Acute Severe Peripartum CardiomyopathyCirculation, 2010
- Prolactin and Preclinical Atherosclerosis in Menopausal Women With Cardiovascular Risk FactorsHypertension, 2009
- Focus on prolactin as a metabolic hormoneTrends in Endocrinology & Metabolism, 2006
- The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapyClinical Endocrinology, 2006
- Macroprolactin does not contribute to elevated levels of prolactin in patients on renal replacement therapyClinical Endocrinology, 2005
- Prolactin stimulates integrin-mediated adhesion of circulating mononuclear cells to endothelial cellsLaboratory Investigation, 2005